A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies
A Phase 1b/2 Study of the ROR1-Targeting Monoclonal Antibody, Cirmtuzumab (UC-961), and the Bruton Tyrosine Kinase Inhibitor, Ibrutinib, in Patients With B-Cell Lymphoid Malignancies
Sponsor: California Institute for Regenerative Medicine (CIRM)
This PHASE1/PHASE2 trial investigates B-cell Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma and is currently completed. California Institute for Regenerative Medicine (CIRM) leads this study, which shows 21 recorded versions since 2018 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
21 versions recorded-
Mar 2025 — Present [monthly]
Completed PHASE1/PHASE2
-
Oct 2024 — Mar 2025 [monthly]
Completed PHASE1/PHASE2
Status: Active Not Recruiting → Completed
-
Sep 2024 — Oct 2024 [monthly]
Active Not Recruiting PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jan 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE1_PHASE2
▶ Show 16 earlier versions
-
Oct 2023 — Jan 2024 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
May 2023 — Oct 2023 [monthly]
Active Not Recruiting PHASE1_PHASE2
Status: Recruiting → Active Not Recruiting
-
Jul 2022 — May 2023 [monthly]
Recruiting PHASE1_PHASE2
Status: Active Not Recruiting → Recruiting
-
May 2022 — Jul 2022 [monthly]
Active Not Recruiting PHASE1_PHASE2
Status: Recruiting → Active Not Recruiting
-
Oct 2021 — May 2022 [monthly]
Recruiting PHASE1_PHASE2
-
Sep 2021 — Oct 2021 [monthly]
Recruiting PHASE1_PHASE2
-
Jan 2021 — Sep 2021 [monthly]
Recruiting PHASE1_PHASE2
-
Aug 2020 — Jan 2021 [monthly]
Recruiting PHASE1_PHASE2
-
Jul 2019 — Aug 2020 [monthly]
Recruiting PHASE1_PHASE2
-
Mar 2019 — Jul 2019 [monthly]
Recruiting PHASE1_PHASE2
-
Feb 2019 — Mar 2019 [monthly]
Recruiting PHASE1_PHASE2
-
Oct 2018 — Feb 2019 [monthly]
Recruiting PHASE1_PHASE2
-
Jun 2018 — Oct 2018 [monthly]
Recruiting PHASE1_PHASE2
-
Jan 2018 — Jun 2018 [monthly]
Recruiting PHASE1_PHASE2
Status: Not Yet Recruiting → Recruiting
-
Dec 2017 — Jan 2018 [monthly]
Not Yet Recruiting PHASE1_PHASE2
-
Apr 2017 — Dec 2017 [monthly]
Not Yet Recruiting PHASE1_PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- California Institute for Regenerative Medicine (CIRM)
- Oncternal Therapeutics, Inc
- Pharmacyclics LLC.
- University of California, San Diego
For direct contact, visit the study record on ClinicalTrials.gov .